Marvel Jessica, Yu Tzy-Chyi, Wood Robert, Higgins Victoria S, Make Barry J
Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Adelphi Real World, Adelphi Group, Bollington, Cheshire, United Kingdom.
Chronic Obstr Pulm Dis. 2016 May 5;3(3):643-652. doi: 10.15326/jcopdf.3.3.2015.0177.
Despite receiving treatment, patients with chronic obstructive pulmonary disease (COPD) often continue to experience symptoms that impact their health status. We determined the relationship between overall symptom burden and health status, and assessed the treatments patients were receiving. Data from 3 cross-sectional surveys of U.S. patients with COPD (2011-2013) were analyzed. Patients receiving inhaled COPD treatment for ≥3 months completed the COPD Assessment Test (CAT) symptom burden and respiratory health status measure, EuroQol 5-dimension (EQ-5D-3L) general health status questionnaire, and Jenkins Sleep Evaluation Questionnaire (JSEQ). CAT scores were used to identify high- (CAT ≥24) and low-symptom patients (CAT <24), who were matched using 1:1 propensity score matching with replacement. Match balance was assessed with standardized mean differences. EQ-5D-3L and JSEQ scores, and current treatment were compared between groups post-matching. Sensitivity was assessed with Rosenbaum bounds. A total of 638 patients were included. Compared with low-symptom patients, high-symptom patients had worse health status and greater sleep disturbance by EQ-5D utility index (0.85 versus 0.71, respectively; <0.0001) and JSEQ scores (3.73 versus 7.35, respectively; <0.0001). High-symptom patients were prescribed single-maintenance bronchodilators ± inhaled corticosteroids (46.0%), triple therapy (40.5%), and short-acting therapy only (8.2%). Results were robust and insensitive to unobserved confounders. Increased COPD symptom burden is associated with worse general health status in patients receiving COPD treatment. High-symptom patients frequently received single inhaled medication. The results suggest that health care providers should monitor and tailor therapy, based on level of symptom burden to improve symptom control and health status.
尽管接受了治疗,但慢性阻塞性肺疾病(COPD)患者仍经常出现影响其健康状况的症状。我们确定了总体症状负担与健康状况之间的关系,并评估了患者正在接受的治疗。对来自美国COPD患者的3项横断面调查(2011 - 2013年)的数据进行了分析。接受吸入性COPD治疗≥3个月的患者完成了慢性阻塞性肺疾病评估测试(CAT)症状负担和呼吸健康状况测量、欧洲五维健康量表(EQ - 5D - 3L)总体健康状况问卷以及詹金斯睡眠评估问卷(JSEQ)。CAT评分用于识别高症状患者(CAT≥24)和低症状患者(CAT < 24),通过1:1倾向评分匹配并替换进行匹配。使用标准化均值差异评估匹配平衡。在匹配后比较两组之间的EQ - 5D - 3L和JSEQ评分以及当前治疗情况。使用罗森鲍姆界限评估敏感性。共纳入638例患者。与低症状患者相比,高症状患者的健康状况更差,EQ - 5D效用指数显示睡眠障碍更大(分别为0.85对0.71;<0.0001),JSEQ评分也更高(分别为7.35对3.73;<0.0001)。高症状患者被处方单维持支气管扩张剂±吸入性糖皮质激素(46.0%)、三联疗法(40.5%)以及仅短期治疗(8.2%)。结果稳健且不受未观察到的混杂因素影响。接受COPD治疗的患者中,COPD症状负担增加与总体健康状况较差相关。高症状患者经常接受单一吸入药物治疗。结果表明,医疗保健提供者应根据症状负担水平监测并调整治疗方案,以改善症状控制和健康状况。